How Abogen went from COVID hype to a $7.8B Novartis deal
After Abogen Biosciences’ COVID shot missed the commercial window, the big question was whether its mRNA technology could create value beyond vaccines. Novartis’ $575 million upfront commitment is the clearest external validation yet of that broader therapeutic potential.
comments(0)
5-min edit window · permanent after that